FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248715042> ?p ?o ?g. }

• W4248715042 endingPage "S283" @default.
• W4248715042 startingPage "S278" @default.
• W4248715042 abstract "Abstract We compared results using Neoral versus Sandimmune, each in combination with steroid and azathioprine immunosuppression, in primary liver transplantation recipients. There were 15 patients in each group with similar demographic distributions. Intravenous cyclosporine was stopped at 4.3 ± 1.9 days in the Neoral group vs 7.8 ± 4.9 days in the Sandimmune group (P < 0.025). Cyclosporine levels in the first 10 days were higher (mean 306 ng/ml vs 231 ng/ml) in the Neoral group than the Sandimmune group (P < 0.05). The Neoral dose was less than the Sandimmune dose (mean 5.5 ng/kg per day vs 7.9 ng/kg per day) to achieve these levels in that time period (P < 0.05). Two patients (13 %) experienced three episodes of biopsy-proven rejection in the Neoral group compared to nine patients (60%) with 12 episodes of rejection in the Sandimmune group (P < 0.025). Incidences of neurological and renal complications were similar between the groups. Infections requiring treatment were also similar. Liver function, renal function, and marrow function, evaluated at days 7, 14, 21, 28, and 2, 4, 6, and 12 months post-transplant, were not different between the groups. In summary, shorter use of intravenous cyclosporine and quicker stabilization of trough cyclosporine levels was achieved with Neoral than with Sandimmune. In the early post-transplant period, higher levels with lower doses were achieved with Neoral than with Sandimmune. In our experience, the incidence of rejection was lower with Neoral than with Sandimmune. There were similar lengths of hospitalization, mortality, adverse events, retransplanta-tion, and similar liver, renal, and marrow function up to 1 year posttransplantation. Because of this experience, we continued to use Neoral in a total of 59 primary liver transplant recipients. We have not used intravenous cyclosporine in the last 44 patients. Follow-up was a mean of 11.4 months, ranging from 1 to 27 months. The incidence of rejection was 24% in these 59 patients compared to our historical experience of 70 % using Sandimmune." @default.
• W4248715042 created "2022-05-12" @default.
• W4248715042 creator A5006826602 @default.
• W4248715042 creator A5033373318 @default.
• W4248715042 creator A5048700369 @default.
• W4248715042 creator A5053188671 @default.
• W4248715042 creator A5055573809 @default.
• W4248715042 creator A5064010266 @default.
• W4248715042 creator A5069604360 @default.
• W4248715042 creator A5076059803 @default.
• W4248715042 creator A5078384640 @default.
• W4248715042 creator A5082257635 @default.
• W4248715042 date "1998-06-01" @default.
• W4248715042 modified "2023-09-25" @default.
• W4248715042 title "Experience with Neoral versus Sandimmune in primary liver transplant recipients" @default.
• W4248715042 cites W1967745415 @default.
• W4248715042 cites W1969837093 @default.
• W4248715042 cites W1997796472 @default.
• W4248715042 cites W2007066337 @default.
• W4248715042 cites W2019935543 @default.
• W4248715042 cites W2038563970 @default.
• W4248715042 cites W2039630367 @default.
• W4248715042 cites W2057388366 @default.
• W4248715042 cites W2078791232 @default.
• W4248715042 cites W2092075764 @default.
• W4248715042 cites W2105293507 @default.
• W4248715042 cites W2151141510 @default.
• W4248715042 cites W4238637783 @default.
• W4248715042 doi "https://doi.org/10.1111/j.1432-2277.1998.tb01134.x" @default.
• W4248715042 hasPublicationYear "1998" @default.
• W4248715042 type Work @default.
• W4248715042 citedByCount "8" @default.
• W4248715042 countsByYear W42487150422018 @default.
• W4248715042 crossrefType "journal-article" @default.
• W4248715042 hasAuthorship W4248715042A5006826602 @default.
• W4248715042 hasAuthorship W4248715042A5033373318 @default.
• W4248715042 hasAuthorship W4248715042A5048700369 @default.
• W4248715042 hasAuthorship W4248715042A5053188671 @default.
• W4248715042 hasAuthorship W4248715042A5055573809 @default.
• W4248715042 hasAuthorship W4248715042A5064010266 @default.
• W4248715042 hasAuthorship W4248715042A5069604360 @default.
• W4248715042 hasAuthorship W4248715042A5076059803 @default.
• W4248715042 hasAuthorship W4248715042A5078384640 @default.
• W4248715042 hasAuthorship W4248715042A5082257635 @default.
• W4248715042 hasBestOaLocation W42487150421 @default.
• W4248715042 hasConcept C126322002 @default.
• W4248715042 hasConcept C126894567 @default.
• W4248715042 hasConcept C54847362 @default.
• W4248715042 hasConcept C71924100 @default.
• W4248715042 hasConceptScore W4248715042C126322002 @default.
• W4248715042 hasConceptScore W4248715042C126894567 @default.
• W4248715042 hasConceptScore W4248715042C54847362 @default.
• W4248715042 hasConceptScore W4248715042C71924100 @default.
• W4248715042 hasIssue "s1" @default.
• W4248715042 hasLocation W42487150421 @default.
• W4248715042 hasOpenAccess W4248715042 @default.
• W4248715042 hasPrimaryLocation W42487150421 @default.
• W4248715042 hasRelatedWork W13079828 @default.
• W4248715042 hasRelatedWork W16690676 @default.
• W4248715042 hasRelatedWork W16998215 @default.
• W4248715042 hasRelatedWork W18396566 @default.
• W4248715042 hasRelatedWork W19878240 @default.
• W4248715042 hasRelatedWork W2241187 @default.
• W4248715042 hasRelatedWork W2700549 @default.
• W4248715042 hasRelatedWork W3933827 @default.
• W4248715042 hasRelatedWork W6634635 @default.
• W4248715042 hasRelatedWork W7567828 @default.
• W4248715042 hasVolume "11" @default.
• W4248715042 isParatext "false" @default.
• W4248715042 isRetracted "false" @default.
• W4248715042 workType "article" @default.